Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib

Abstract Previous studies demonstrated codon-specific KRAS mutation as a potential biomarker of resistance in metastatic colorectal cancer (mCRC). Our study aimed to evaluate the association of RAS status on survival in patients with mCRC treated with trifluridine/tipiracil (FTD/TPI) or regorafenib....

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Meng-Che Hsieh, Kun-Ming Rau, Kuang-Wen Liu, Chong-Chi Chiu, Chih-I Chen, Ling-Chiao Song, Hsin-Pao Chen
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Nature Portfolio 2026-01-01
Reeks:	Scientific Reports
Onderwerpen:	Metastatic colorectal cancer Trifluridine/tipiracil RAS status
Online toegang:	https://doi.org/10.1038/s41598-026-36509-y
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!